Abstract
A case study is described of a patient who was intoxicated after the intake of so‐called herbal stimulants. A visit to a physician after the intoxication prompted to this investigation and the case was examined for its direct cause. An interview with the patient revealed that the source of the herbal stimulants was a so‐called 'S‐5 tablet'. Information provided on the packings of the tablet only indicated the presence of natural alkaloids and vitamines. Toxicological analysis however proved that the 'S‐5 tablet' contained para‐methylthioamphetamine (MTA), mainly. MTA is a relative unknown amphetamine designer drug, which has only been studied as a model compound in some structure‐activity relationship studies. The fact that MTA appeared in tablets was therefore completely unexpected. Not only the potential abuse of this new amphetamine designer drug is a serious matter of concern, but also the misleading information provided with the tablet.
Similar content being viewed by others
References
Valtier S, Cody JT. Evaluation of internal standards for the analysis of amphetamine and metamphetamine. J Anal Tox 1995;19:375-80.
Solans A, Carnicero M, De la Torre R, Segura J. Comprehensive screening procedure for the detection of stimulants, narcotics, adrenergic drugs, and their metabolites in human urine. J Anal Tox 1995;19:104-14.
Shulgin A, Shulgin A. PIHKAL. A chemical love story. 1st ed. Berkeley: Transform Press, 1992:707.
Huang H, Marona-Lewicka D, Nichols DE. p-Methylthioamphetamine is a potent new non-neurotoxic serotonin releasing agent. Eur J Pharmacol 1992;229:31-8.
Li Q, Murakami I, Stall S, Levy AD, Brownfield MS, Nichols DE, Van de Kar LD. Neuroendocrine pharmacology of 3 serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-butane (MBDB), 5-methoxy-6-methyl-2-aminoindane (MMAI) and p-methylthioamphetamine (MTA). J Pharmacol Exp Ther 1996;279:1261-7.
Rights and permissions
About this article
Cite this article
de Boer, D., Maes, R.A. & Egberts, T. Para‐methylthioamphetamine, a new amphetamine designer drug of abuse. Pharm World Sci 21, 47–48 (1999). https://doi.org/10.1023/A:1008695807837
Issue Date:
DOI: https://doi.org/10.1023/A:1008695807837